Donald P. Quick

1.4k total citations
39 papers, 885 citations indexed

About

Donald P. Quick is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Donald P. Quick has authored 39 papers receiving a total of 885 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Hematology and 11 papers in Genetics. Recurrent topics in Donald P. Quick's work include Multiple Myeloma Research and Treatments (13 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Cancer Treatment and Pharmacology (9 papers). Donald P. Quick is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Cancer Treatment and Pharmacology (9 papers). Donald P. Quick collaborates with scholars based in United States, United Kingdom and Canada. Donald P. Quick's co-authors include Peter J. Ell, Robert H. Reid, Oliver Sartor, Leonărd M. Freeman, Philippe Olivier, Robert E. Coleman, Jon Kotler, Peter Hoskin, David Bushnell and F. R. Ahmann and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Donald P. Quick

36 papers receiving 865 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donald P. Quick United States	12	554	461	401	215	84	39	885
Marie‐Cécile Bozonnat France	7	710 1.3×	414 0.9×	1.6k 3.9×	159 0.7×	52 0.6×	12	1.9k
Clive Sinoff Canada	7	1.2k 2.1×	502 1.1×	353 0.9×	319 1.5×	121 1.4×	10	1.4k
Peter G. Sørensen Denmark	16	529 1.0×	170 0.4×	225 0.6×	308 1.4×	79 0.9×	43	1.1k
S. Bourdin France	15	326 0.6×	197 0.4×	432 1.1×	264 1.2×	47 0.6×	40	887
Florian Kocher Austria	18	498 0.9×	117 0.3×	357 0.9×	130 0.6×	49 0.6×	72	990
Federica Matteucci Italy	21	456 0.8×	599 1.3×	664 1.7×	123 0.6×	27 0.3×	86	1.3k
Michael Mac Manus Australia	12	283 0.5×	341 0.7×	375 0.9×	103 0.5×	21 0.3×	20	777
Dries Reynders Belgium	11	285 0.5×	410 0.9×	854 2.1×	207 1.0×	21 0.3×	22	1.2k
L. Falchero France	18	673 1.2×	333 0.7×	1.0k 2.5×	127 0.6×	14 0.2×	71	1.4k
M.A. Neben-Wittich United States	13	284 0.5×	124 0.3×	252 0.6×	229 1.1×	59 0.7×	59	769

Countries citing papers authored by Donald P. Quick

Since Specialization

Citations

This map shows the geographic impact of Donald P. Quick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald P. Quick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald P. Quick more than expected).

Fields of papers citing papers by Donald P. Quick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald P. Quick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald P. Quick. The network helps show where Donald P. Quick may publish in the future.

Co-authorship network of co-authors of Donald P. Quick

This figure shows the co-authorship network connecting the top 25 collaborators of Donald P. Quick. A scholar is included among the top collaborators of Donald P. Quick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald P. Quick. Donald P. Quick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bahlis, Nizar J., Christy Samaras, Donna Reece, et al.. (2024). Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014. Clinical Lymphoma Myeloma & Leukemia. 24(12). 852–862. 2 indexed citations

Yalamanchili, Kiran, et al.. (2024). Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy. SHILAP Revista de lepidopterología. 7(4). 91–91. 1 indexed citations

Bahlis, Nizar J., Christy Samaras, Donna Reece, et al.. (2023). MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S494–S495. 1 indexed citations

Bahlis, Nizar J., Christy Samaras, Donna Reece, et al.. (2023). P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY. HemaSphere. 7(S3). e757660c–e757660c. 1 indexed citations

Maurer, Barry J., Min H. Kang, C. Patrick Reynolds, et al.. (2023). Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies. Cancer Chemotherapy and Pharmacology. 92(2). 97–105. 3 indexed citations

Bahlis, Nizar J., Gary J. Schiller, Christy Samaras, et al.. (2022). P-232: Adverse event patterns and management with pomalidomide, dexamethasone, and daratumumab in patients with relapsed or refractory multiple myeloma: a safety analysis of the phase 2 MM-014 study. Clinical Lymphoma Myeloma & Leukemia. 22. S162–S163. 1 indexed citations

Kopel, Jonathan, et al.. (2020). Sequential Complications of Hypercalcemia, Necrotizing Granulomatous Vasculitis, and Aplastic Anemia Occurring in One Patient with Angioimmunoblastic T-cell Lymphoma. The American Journal of the Medical Sciences. 361(3). 375–382.

Thein, Kyaw Zin, et al.. (2020). Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy. Lung. 198(3). 575–579. 5 indexed citations

Thein, Kyaw Zin, Donald P. Quick, & Thein Hlaing Oo. (2019). Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy. Blood. 134(Supplement_1). 3469–3469. 1 indexed citations

10.

Tun, Aung M., et al.. (2019). Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab. Blood. 134(Supplement_1). 4771–4771. 5 indexed citations

11.

Pettengell, Ruth, Monika Długosz‐Danecka, David Andorsky, et al.. (2019). Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B‐cell non‐Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). British Journal of Haematology. 188(2). 240–248. 12 indexed citations

12.

Palandri, Francesca, Maria R. Baer, Donald P. Quick, et al.. (2018). Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. Leukemia Research. 71. 82–88. 41 indexed citations

13.

Salles, Gilles, Wojciech Jurczak, David Andorsky, et al.. (2018). Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation. Blood. 132(Supplement 1). 4189–4189. 3 indexed citations

14.

Georgiev, Pencho, David Belada, Shaker R. Dakhil, et al.. (2016). Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma. Annals of Oncology. 27. vi324–vi324.

15.

Czuczman, Myron S., Stephen P. Kahanic, Andres Forero, et al.. (2015). Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin’s lymphoma. Annals of Hematology. 94(4). 633–641. 22 indexed citations

16.

Higano, Celestia S., Donald P. Quick, David Bushnell, & Oliver Sartor. (2008). Safety Analysis of Repeated High Doses of Samarium-153 Lexidronam in Men with Hormone-Naive Prostate Cancer Metastatic to Bone. Clinical Genitourinary Cancer. 6(1). 40–45. 5 indexed citations

17.

Sartor, Oliver, Robert H. Reid, David Bushnell, Donald P. Quick, & Peter J. Ell. (2006). Safety and efficacy of repeat administration of samarium Sm‐153 lexidronam to patients with metastatic bone pain. Cancer. 109(3). 637–643. 85 indexed citations

18.

Sartor, Oliver, Robert H. Reid, Peter Hoskin, et al.. (2004). Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 63(5). 940–945. 254 indexed citations

19.

Serafini, A. N., I. Resche, Donald P. Quick, et al.. (1998). Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.. Journal of Clinical Oncology. 16(4). 1574–1581. 310 indexed citations

20.

Yau, Jonathan C., Pierre L. Triozzi, Shailendra Verma, et al.. (1996). Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. American Journal of Hematology. 51(4). 289–295. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact